63 Million Doses of Moderna's New COVID-19 Variant Vaccine Introduced

Sequential Import of 2 Million Doses Including Free Vaccinations for Those Aged 65 and Over

The Korea Disease Control and Prevention Agency announced that approximately 630,000 initial doses of the Moderna vaccine for the 2024-2025 COVID-19 new variant (JN.1) vaccination will be introduced on the 23rd and 24th.

[Image source=Yonhap News]

The new Moderna vaccine is a domestically manufactured vaccine produced by Samsung Biologics, which receives the active pharmaceutical ingredient from Moderna. It received approval from the Ministry of Food and Drug Safety on the 11th, and a total of 2 million doses, including the initial batch, will be introduced sequentially.

The total vaccine supply secured for this season is 5.23 million doses of Pfizer, 2 million doses of Moderna, and 320,000 doses of Novavax, totaling 7.55 million doses. The Novavax vaccine will be introduced after emergency use authorization is completed.

The vaccine support targets are those aged 65 and older, immunocompromised individuals, and residents or inpatients of infection-vulnerable facilities. Those aged 75 and older, immunocompromised individuals, and residents or inpatients of infection-vulnerable facilities can receive the vaccine starting from the 11th of next month, those aged 70-74 from October 15, and those aged 65-69 from the 18th.

This content was produced with the assistance of AI translation services.